--- title: "Core — The data engine" description: "Eight data layers, 500M+ documents, one engine. Literature, scholarly papers, trials, drugs, genes, patents, FDA + EMA regulatory, and real-time web sources — every answer cited to source." url: https://amass.tech/core --- # Core — The data engine Amass \*Core # Eight specialised data layers. One retrieval engine. One query searches literature, scholarly papers, trials, drugs, genes, patents, regulatory docs, and real-time web sources in parallel. Every answer cites its source — a DOI, NCT ID, or patent number. No hallucination. [Start Building →](https://amass.tech/life-science-api)[Book a Demo](https://amass.tech/demo) Architecture ## How a query fans out and comes back cited You send one natural-language query. The engine dispatches to every relevant layer simultaneously, merges results, and returns a single JSON response with citations attached to each claim. Data Sources PubMedPMCCrossrefUSPTOEPOWIPOSureChEMBLFDAEMAClinicalTrials.govWHO ICTRPHGNCEnsemblUniProtChEMBLWeb Amass \*Core Engine BiomedCore 40M+ ScholarCore 233M+ PatentCore 16M+ RegulatoryCore FDA + EMA DrugCore 22K+ TrialCore 1.2M+ GeneCore 43K+ WebCore Live Cited Outputs Reports·Cited Q&A·Alerts·JSON API ### BiomedCore PubMed & PMC papers indexed BiomedCore ## 40M+ PubMed and PMC papers — full text, MeSH-indexed - Full PubMed and PubMed Central coverage — abstracts and full text - Citation counts, journal impact metrics, and quality signals - Ideal for systematic literature reviews and evidence synthesis - MeSH-enriched metadata for precise filtering PubMedPMID 38420693 SGLT2 inhibitors in heart failure with preserved ejection fraction Solomon SD, McMurray JJV, et al. N Engl J Med (2024) ### ScholarCore Scholarly papers across all disciplines ScholarCore ## 233M+ papers, preprints and conference proceedings - Journal articles, preprints and conference proceedings - Cross-disciplinary reach beyond the biomedical literature - Reaches work that has not yet appeared in BiomedCore ### PatentCore Life-science patents indexed PatentCore ## 16M+ patent publications — full text, families, and cross-links to drugs and papers - 16.8M publications across every major office — US, EP, WIPO/PCT, CN, JP, KR, and more - Full-text search over title, abstract, claims, and description - CPC/IPC classifications, assignees, inventors, and four dates — priority, filing, publication, grant - Search collapses each family to one publication, so a landscape isn't flooded with near-duplicates - 12.5M patents linked to a drug in DrugCore; citation lineage and references into BiomedCore PatentUS-8815802-B2 GLP-1 analogues and derivatives Assignee: Novo Nordisk A/S Filed: 2010-12-16 ### RegulatoryCore FDA & EMA documents indexed RegulatoryCore ## FDA and EMA on one schema — approvals, labels, EPARs, and designations - FDA application records, drug labels, review documents, and approval letters - EMA EPARs, assessment reports, and SmPCs — European authorizations in full - Unified authorization status, plus Breakthrough, PRIME, and Accelerated Approval designations - Orphan tracking, cross-linked to the drug each authorization covers in DrugCore FDANDA 761248 Donanemab (Kisunla) Early symptomatic Alzheimer's disease Approved: 2024-07-02 ### DrugCore ChEMBL drugs & molecules indexed DrugCore ## 22K+ harmonized drugs and molecules — modality, clinical stage, and structure - ChEMBL-derived drug records — names, trade names, and synonyms, harmonized - Chemical structures with InChIKey and SMILES, plus modality classification - Highest clinical stage reached, from preclinical through approval - Parent/child relationships, cross-linked to trials, literature, and regulatory records ProteinApprovedCHEMBL2108724 Semaglutide Ozempic · Wegovy · Rybelsus 6 approved · 30 investigational ### TrialCore Clinical trials indexed TrialCore ## 1.2M+ trials from ClinicalTrials.gov and international registries — status, endpoints, sponsor - ClinicalTrials.gov + international registries — 590K+ and 610K+ — with AI-enhanced search - Enrollment status, endpoints, and sponsor intelligence - Phase, indication, and comparator filtering - Trial-to-publication linking for evidence completeness Phase 3Active NCT04931681 Semaglutide vs placebo in NASH with fibrosis Sponsor: Novo Nordisk ### GeneCore Human genes indexed GeneCore ## 43K+ harmonized human genes — druggability, constraint, and cross-linked to DrugCore - HGNC, NCBI, UniProt, and Ensembl — harmonized on one schema - Druggability and tractability assessments, by modality and clinical precedent - Genetic constraint via gnomAD v4.0 — pLI and LOEUF loss-of-function scores - Cellular essentiality from CRISPR dependency screens — genes required for cell survival - Each gene cross-links to the drugs that target it in DrugCore, and the trials and papers studying it ### WebCore Real-time web sources WebCore ## Real-time web sources, including company sites, press releases and conference news - Company sites, press releases and conference news - Current events that no fixed corpus has indexed yet - Cited the same way as every other source Capabilities ## What you get back from every query ### Cited answers Every claim traces back to a source document. Inline citations, not hallucinated references. ### Unified retrieval Query once. All 8 layers respond in parallel. No need to stitch results across different databases. ### Agent execution Built-in agents plan multi-step research workflows, iterate on results, and deliver structured output. ### Enterprise controls Role-based access, audit logging, and data residency options for regulated environments. ### API & MCP access REST API for custom integrations. MCP server for Claude, ChatGPT, and Cursor — same engine, your interface. ### Structured outputs Tables, JSON, and tagged extracts. Get machine-readable results, not just paragraphs of text. Get started ## Query 500M+ documents from your terminal in five minutes Get your first cited response in under five minutes. No prior knowledge of the data layers required. [Start Building →](https://amass.tech/life-science-api)[Book a Demo](https://amass.tech/contact)